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Abstract
Background: We have previously described a panel of 238 urinary polypeptides specific for established severe
coronary artery disease (CAD). Here we studied this polypeptide panel in patients with a wider range of CAD
severity.
Methods: We recruited 60 patients who underwent elective coronary angiography for investigation of stable angina.
Patients were selected for either having angiographic evidence of CAD or not (NCA) following coronary angiography
(n = 30/30; age, 55 ± 6 vs. 56 ± 7 years, P = 0.539) to cover the extremes of the CAD spectrum. A further 66 patients
with severe CAD (age, 64 ± 9 years) prior to surgical coronary revascularization were added for correlation studies. The
Gensini score was calculated from coronary angiograms as a measure of CAD severity. Urinary proteomic analyses were
performed using capillary electrophoresis coupled online to micro time-of-flight mass spectrometry. The urinary
polypeptide pattern was classified using a predefined algorithm and resulting in the CAD238 score, which expresses the
pattern quantitatively.
Results: In the whole cohort of patients with CAD (Gensini score 60 [40; 98]) we found a close correlation between
Gensini scores and CAD238 (ρ = 0.465, P < 0.001). After adjustment for age (β = 0.144; P = 0.135) the CAD238 score
remained a significant predictor of the Gensini score (β =0.418; P < 0.001). In those with less severe CAD
(Gensini score 40 [25; 61]), however, we could not detect a difference in CAD238 compared to patients with
NCA (−0.487 ± 0.341 vs. −0.612 ± 0.269, P = 0.119).
Conclusions: In conclusion the urinary polypeptide CAD238 score is associated with CAD burden and has
potential as a new cardiovascular biomarker.
Keywords: Coronary artery disease, Urinary proteomics, Stable angina
Background
Stable angina, with an estimated prevalence of 2–4 % in
most European countries [1], is a common disorder.
Contemporary guidelines recommend assessment of pa-
tients with suspected angina with a variety of non-
invasive tests for diagnostic purposes [1, 2]. For reasons
of availability, cost and test performance there is a need
for new diagnostic tests to contribute to the diagnostic
process of stable angina.
Recent advances in proteomics have allowed studies
into new biomarkers of cardiovascular disease [3]. A
variety of biofluids can be subject to proteomic analysis,
yet for clinical applications urine has several advantages
over blood [4]. Polypeptide expression patterns in urine
can represent a “peptide finger print” of a disease and
can therefore function as a disease specific biomarker.
We have previously developed a urinary proteome sig-
nature specific for coronary artery disease (CAD). An
initial small study characterized a 15-biomarker panel
with sensitivity and specificity to predict the presence of
CAD of 98 and 83 %, respectively [5]. In our most recent
study in a total of 623 individuals, a 238-biomarker
panel in patients and controls from different centers was
validated and filtered against concomitant disease and
treatment-specific effects. The panel had a sensitivity of
79 % and a specificity of 88 % for the diagnosis of CAD
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[6]. The majority of CAD patients in this cohort had severe
CAD and was scheduled for surgical revascularization.
Here, in a scenario closer to potential clinical use, we
investigated whether the 238-biomarker panel (CAD238)
could also differentiate patients with less extensive CAD
from patients without angiographic evidence of CAD
(NCA).
Methods
Study end points
The primary end point of this study was the differenti-
ation of significant CAD from NCA by the CAD238
score in patients with stable angina like chest pain. Sec-
ondary end points included: CAD238 score correlation
with CAD extent/severity; evaluation of potential co-
founding factors and assessment of the CAD238 scores
capacity to identify prognostic relevant CAD.
Patients
Study participants were referred by local cardiologists
for further investigations of typical symptoms and/or
positive non-invasive tests to the Golden Jubilee
National Hospital, Clydebank, UK, and underwent
elective coronary angiography in 2009. From all pa-
tients (n = 1380) we selected those with significant
CAD, defined as at least one coronary artery stenosis
≥75 % of the artery lumen; or NCA, defined as the ab-
sence of any angiographic evidence of CAD. Study
visits took place in 2010, 286 (58 to 459) days after the
coronary angiography/percutaneous intervention, and
included urine sample collection. Patients were ex-
cluded for the following reasons: history of established
CAD, acute coronary syndromes, previous organ trans-
plantation, heart failure, malignant concomitant dis-
eases within the last 5 years, systemic inflammatory
diseases or severe liver diseases. Based on medical rec-
ord information, residence within 13 miles of the study
centre and availability of contact information, 260 eli-
gible patients were invited of whom 87 agreed to par-
ticipate (Additional file 1: Figure S1). Six patients had
to be excluded following assessment at the study visit.
Of the remaining participants, we selected a cohort of
30 patients with CAD and 30 age-matched patients
with NCA for proteomic analysis.
Further cases and controls from a previous study [6]
were included in the quantitative analyses in the present
study in order to represent the spectrum of CAD from
NCA to severe CAD requiring surgical revascularization.
The cases consisted of patients with severe coronary ar-
tery disease confirmed by coronary angiography (n = 66)
who were recruited at the pre-assessment clinic on the
day prior to elective coronary artery bypass grafting
(CABG). The controls were healthy volunteers without
evidence of CAD (n = 67).
All participants gave written informed consent. The
study was approved by the West of Scotland Research
Ethics Committee and is in keeping with the principles
of the Declaration of Helsinki.
Gensini score
To quantify the overall CAD extent the scoring system
suggested by Gensini [7] was used. Stenoses of less than
25, 25–49, 50–74, 75–94, 95–99 and 100 % were
equated with 1, 2, 4, 8, 16 and 32, accordingly. Depend-
ing on the artery segment and dominance of the left or
right coronary artery, these scores were multiplied with
factors from 0.5 to 5 [7] to implement the functional sig-
nificance of the area supplied by that segment. The ar-
tery segment scores were finally added to obtain the
Gensini score. If not stated otherwise, reported Gensini
scores are based on angiographic findings prior to per-
cutaneous intervention.
Carotid intima media thickness
Measurement of carotid intima media thickness was
performed by ultrasonography (Acuson Sequoia C512,
Siemens, Erlangen, Germany) with an 8 MHz linear-
array transducer. The carotid intima-media thickness of
the left and right common carotid was measured in the
far wall, 1 cm proximal of the carotid bulb in a plaque
free region in accordance with the Mannheim consensus
[8]. ECG signals were stored simultaneously to define
the systolic and diastolic phase of the cardiac cycle. Off-
line measurements were performed semi-automatically
at end diastole on B-mode images using Image-Pro Plus
software, version 3.0 (Media Cybernetics, Bethesda,
USA). Reported carotid intima-media thickness repre-
sents the mean of all taken measurements.
Sample collection
Routine urine and blood samples were collected ac-
cording to local standards and analyzed in laborator-
ies at Gartnavel General Hospital, Glasgow, UK.
Urine samples for proteomics were stored at −80 °C
at the BHF Glasgow Cardiovascular Research Centre.
Proteome analysis was carried out at Mosaiques Diag-
nostics, Hannover, Germany.
Urinary proteomics
All samples were prepared by ultrafiltration, desalting
and lyophilisation, as described in detail previously [9].
Prior to CE-MS analysis, samples were resuspended with
high performance liquid chromatography grade water to
yield 0.8 g/L protein concentration as measured by
bicinchoninic acid assay (Interchim, Montlucon, France).
CE-MS analysis was performed as previously described
[10] using a P/ACE MDQ capillary electrophoresis sys-
tem (Beckman Coulter) online coupled to a time-of-
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flight mass spectrometer (micro-time- of-flight MS;
Bruker Daltonic). Spectra were accumulated every 3 s
over a range of mass-to-charge ratios from 350 to 3000.
Accuracy, precision, selectivity, sensitivity, reproducibil-
ity, and stability using this technique are described in
detail elsewhere [9]. In brief, the detection limit is in the
range of 1 fmol, depending on the ionization properties
of the individual peptide. In a urine sample, the detec-
tion limit in the crude sample before processing is 100
to 1000 fmol/mL. Platform validation was performed as
described previously [11].
MosaiquesVisu (mosaiques diagnostics and therapeu-
tics AG, Hannover, Germany) was employed for mass
spectrometry data processing. Data were normalized
based on reference signals from 29 abundant “house-
keeping” peptides generally present in urine, which are
the result of normal biological processes and are not af-
fected by age, sex, or disease state [12]. The individual
sample data were calibrated with a local regression algo-
rithm and 29 internal standard peptides, all collagen
fragments [12], as reference. After normalization signal
intensity was employed as a marker for relative quantity.
Statistics
A power calculation (1-β = 0.95, α = 0.05) was conducted
to evaluate the number of subjects necessary to detect a
significant CAD238 score difference. Based on our previ-
ous data [6] (Additional file 1: Table S1) 12 patients in
each group were required for the actual power 0.96. To
account for any analytical difficulties we opted for a con-
venience sample of 30 patients per group.
Data were analyzed using SPSS software, version 15.0
(SPSS Inc., Chicago, USA). The CAD238 score corre-
sponding to a CAD specific urinary polypeptide pattern
was calculated as published by Delles et al. [6]. Normal-
ity of data distribution for all experiments was tested
using the Kolmogorov-Smirnov test and visual inspec-
tion of Q-Q plots. Correlations were assessed by calcu-
lating Pearson’s or Spearman’s correlation coefficient for
parametric and non-parametric data, respectively. The
two sample Student’s t test or the Mann Whitney test
was conducted as appropriate for the comparison of two
groups of paired observations for continuous data. For
comparison of categorical data of independent groups
the Chi-squared test was employed.
Results
Cardiovascular risk factors were similar in patients with
or without angiographic evidence of CAD (Table 1).
Similarly, in patients with angina like chest pain the
CAD238 score was not significantly different between pa-
tients with CAD and those with NCA (−0.487 ± 0.341 vs.
−0.612 ± 0.269, P = 0.119) as shown in Fig. 1. To adjust
for potential cofounding factors we used a stepwise linear
regression model with CAD238 score, age, gender and dia-
betes status as predictors of CAD. The resulting model
contained only the CAD238 score (β = 0.206; P = 0.090)
and gender (β = 0.128; P = 0.092), but remained statisti-
cally non-significant (P = 0.072).
In order to increase the sample size of our study and
to cover a wider spectrum of severity of CAD for correl-
ation analyses we added data from patients with severe
CAD who were due to undergo CABG surgery
(Additional file 1: Table S1). The complete CAD cohort
(n = 96 patients) is summarized in Additional file 1:
Table S2.
The Gensini score was different in patients with stable
angina and CAD compared to CAD patients undergoing
CABG (40 [25; 61] vs. 77 [56; 109]; P < 0.001). When all
patients with CAD were combined (n = 96) the CAD238
score correlated closely with the Gensini score (ρ = 0.465,
P < 0.001; Fig. 2). Due to the difference in age between
patients with CAD and stable angina and those prior to
surgical coronary revascularization (55.1 ± 6.0 vs. 64.3 ±
8.8 years, P < 0.001), we adjusted for age using a linear
regression model. After adjustment for age (β = 0.144;
P = 0.135) the CAD238 score remained a significant
predictor of the Gensini score (β =0.418; P < 0.001).
To evaluate if factors other than CAD severity influ-
ence the CAD238 score, we studied control subjects, i.e.
those without evidence of CAD (n = 97) (Additional file
1: Table S2). Medication such as beta-blockers, statins,
calcium channel blockers, aspirin or angiotensin con-
verting enzyme inhibitors/angiotensin receptor blockers
(Additional file 1: Figure S2) as well as cardiovascular
risk factors such as hypertension (yes vs no, n = 35/58,
−0.507 ± 0.344 vs −0.518 ± 0.307, P = 0.877), dyslipidaemia
(yes vs no, n = 42/45, −0.486 vs −0.545, P = 0.403), smok-
ing history (yes vs no, n = 43/44, −0.542 ± 0.348 vs −0.498
± 0.300, P = 0.510), and diabetes (yes vs no, n = 4/93,
−0.795 [−0.850; −0.73] vs −0.560 [−0.738; −0.302], P =
0.280) did not impact on the CAD238 score. There was
also no difference in CAD238 score between men (n = 50)
and women (n = 47) (−0.480 ± 0.310 vs. −0.568 ± 0.332, P
= 0.178). In patients without angiographic evidence of
CAD, the CAD238 score correlated with age as shown in
Additional file 1: Figure S3. There was no statistically
significant correlation between the CAD238 score and
carotid intima media thickness in CAD patients (n = 73; ρ
= −0.078, P = 0.510) and control subjects (n = 70; r = 0.011,
P = 0.926) and thereby no evidence for influences of non-
cardiac atherosclerosis on the score.
In 77 % of patients with CAD percutaneous coronary
intervention (PCI) was performed prior to urine collec-
tion. Considering the correlation between the CAD238 and
Gensini score we investigated the potential PCI effect on
the urine polypeptide pattern. The Gensini score was
recalculated by subtraction of stented artery segment
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(Gensinicorrected vs. Gensini score, 6.00 [3.75; 25.25] vs.
35.00 [22.63; 52.38], P = 0.001). Using the median of the
Gensinicorrected score as cut-off the comparison of patients
with CAD (n = 14) and NCA was repeated (Additional file
1: Figure S4). The difference in CAD238 score between pa-
tients with CAD and a Gensinicorrected score >6 and those
with NCA was statistically significant (−0.395 ± 0.386 vs.
−0.612 ± 0.269, P = 0.036). We used a stepwise linear re-
gression model with CAD238 score, age, gender and
diabetes status as predictors of CAD to adjust for po-
tential cofounding factors. The resulting model con-
tained only the CAD238 score (β = 0.208; P = 0.053)
and gender (β = 0.131; P = 0.025) and remained statis-
tically significant (P = 0.014). Additionally, we corre-
lated the corrected Gensini score with the CAD238
score. The result (ρ = 0.560, P < 0.001) was similar to
the correlation between Gensini and CAD238 scores.
To estimate a potential value of urine proteomics for
the identification of patients with prognostic relevant
CAD, we investigated the relationship between the
CAD238 score and specific angiographic findings in the
complete CAD cohort. In accordance with current
guidelines [13] prognostically relevant CAD was defined
as left main stenosis ≥50 %, three-vessel disease or two-
vessel disease including the proximal left anterior de-
scending artery (each with stenosis ≥70 %). The CAD238
score difference between prognostically relevant and
non-relevant CAD was statistically significant (n = 64/32;
0.059 ± 0.442 vs. −0.361 ± 0.416, P < 0.001).
Discussion
The main finding of the present study is the significant as-
sociation between the CAD238 score and extent of CAD.
However, contrary to our hypothesis, the CAD238 score
was not different between patients with chest pain who
had CAD and patients with chest pain who had NCA.
The retrospective design of our study may account for this
apparently negative finding; correcting CAD extent for the
treatment effect of PCI resulted in a statistically significant
CAD238 score difference between patients and controls.
Table 1 Cohort characteristics of stable angina patients with CAD and NCA
CAD, n = 30 NCA, n = 30 P-value
CAD238 score −0.487 ± 0.341 −0.612 ± 0.269 0.119
ACR (all > detection limit) 0.9 [0.6; 2.0] 1.6 [1.0; 3.4] 0.036
Age, years 55.1 ± 6.0 56.1 ± 7.0 0.539
Sex, m/f 16/14 10/20 0.192
BMI, kg/m2 27.9 ± 4.2 28.8 ± 7.5 0.605
SBP, mmHg 138 ± 17 138 ± 19 0.976
DBP, mmHg 78 ± 10 81 ± 9 0.205
Heart rate,/min 57 ± 9 59 ± 9 0.321
Total cholesterol, mmol/l 4.3 [3.8; 5.6] 4.8 [4.3; 5.7] 0.077
LDL-cholesterol, mmol/l 2.1 [1.8; 3.3] 2.4 [2.0; 3.4] 0.533
HDL-cholesterol, mmol/l 1.2 [0.9; 1.4] 1.3 [1.0; 1.6] 0.286
Triglycerides, mmol/l 1.6 [1.1; 2.1] 1.7 [1.1; 2.5] 0.404
Hypertension history, % 77 57 0.438
CAD family history, % 73 70 1.000
Diabetes history, % 20 13 0.299
Active smoking, % 23 17 0.747
Statin, % 87 57 0.020
Aspirin, % 93 33 <0.001
Beta-blocker, % 83 27 <0.001
ACEI/ARB, % 40 33 0.789
Gensini-score 40 [25; 61] 0 –
Corrected Gensini-score ‡ 8 [4; 40] 0
Carotid IMT, mm 0.724 [0.677; 0.802] a 0.753 ± 0.092 # 0.444
Data are given as mean ± SD or median [ICR] as appropriate. P-values are from Student’s t-test, Mann–Whitney U-test, Chi-square test or Fisher’s exact test where
appropriate. ACEI angiotensin-converting enzyme inhibitor, ACR albumin-creatinine ratio, ARB angiotensin receptor blocker, BMI body mass index, CAD coronary
artery disease, DBP diastolic blood pressure, IMT intima-media thickness, NCA normal coronary arteries, HDL high-density lipoprotein, LDL low-density lipoprotein,
SBP systolic blood pressure, ‡ Gensini-score after percutaneous intervention; a n = 29; # n = 28
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Urinary proteomics and CAD
Urinary polypeptide patterns have been found to differenti-
ate between patients with and without CAD in a variety of
clinical situations such as unstable angina [14] and asymp-
tomatic individuals with high cardiovascular risk [15]. To
allow diagnosis of CAD independent of the clinical scenario
we previously developed a urinary proteomics-derived pat-
tern consisting of 238 polypeptides [6]. In the present study
we evaluated the corresponding CAD238 score in patients
with or without angiographic CAD.
In contrast to our previous studies in which the
CAD238 score was developed and validated [6] we have
chosen the present study design in order to look into
less extreme phenotypes. The study represents a proof
of concept study closer to clinical practice [16]. The
diagnostic validation of the CAD238 score [16] for in-
stance in patients with intermediate cardiovascular risk
and stable angina [1, 2] does however require further in-
vestigations and further refinement of the CAD specific
urine polypeptide pattern.
Scoring systems of coronary angiograms target differ-
ent qualities. The Syntax score, for instance, evaluates
CAD complexity [17]. For this study we chose the
Gensini Score [7] in order to quantify CAD extent/se-
verity. In the past the Gensini score has been associated
with inflammation [18], systemic atherosclerosis [19],
peripheral vascular disease [20], renal impairment [21]
and the chromosome 9p21 risk locus [22] emphasising
its value in CAD assessment.
Gensini scores in patients with CAD and stable angina in
the present study were lower than those in patients await-
ing CABG in our previous biomarker validation study,
confirming the expected less pronounced coronary athero-
sclerosis in the present cohort [6]. Also, the majority of
patients with CAD and stable angina underwent PCI in-
cluding stent insertion prior to urine collection. Interven-
tion leads to extensive arterial wall remodeling and
neointima formation [23, 24]. The altered physiology of the
stented artery segment is therefore expected to impact on
the CAD238 score. We therefore accounted for the reduc-
tion of atherosclerotic wall segments in contact with the
blood stream after PCI. The difference in CAD238 score be-
tween control subjects and patients with remaining signifi-
cant coronary artery atheroma after PCI, represented by a
Gensini score >6, was statistically significant. The interven-
tion probably contributed to a “healthier” CAD238 score in
patients with stable angina and CAD than in those sched-
uled for surgical coronary revascularization who were pre-
viously studied.
We found, however, a strong correlation between the
Gensini score and the CAD238 score. The Gensini score
was designed to reflect on the number of diseased cor-
onary arteries, their importance regarding dependent
myocardial mass and the extent of arterial narrowing
[7]. The score therefore provides a measure of CAD ex-
tent. In extensive CAD the surface area of plaque will be
larger. Therefore more atherosclerosis related peptides
will enter the blood stream and can be subsequently de-
tected in the urine.
In our cohort carotid intima-media thickness and the
CAD238 score were not correlated. As carotid intima-
media thickness is a marker of early atherosclerosis, the
finding suggests the independence of the CAD238 score
from non-cardiac atherosclerosis.
Next to the diagnosis of significant CAD in stable an-
gina patients, the identification of prognostic relevant
CAD holds clinical value. Several predictors of prognostic-
ally relevant CAD are known [25]. Considering the
Fig. 2 Correlation between CAD238 score and the Gensini score. The
Gensini score (y-axis) is plotted against the CAD238 score (x-axis) for
96 patients. Shown are the Spearman’s correlation coefficient and
the corresponding P-value
Fig. 1 CAD238 score comparison between patients with NCA and
CAD. Lines represent the mean. NCA normal coronary arteries, CAD
coronary artery disease
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significant CAD238 score difference between prognostic-
ally relevant and non-relevant CAD in our cohort, urine
proteomics has also potential to identify patients with
such disease and to direct therapies to high-risk patients.
Collagen turnover assessment by urinary proteomics
Most peptides in the CAD238 panel were collagen frag-
ments [6]. As the collagen content in artery walls in-
creases with age [26], leading to increased arterial wall
stiffness, this might explain the score’s correlation with
age. Altered degradation of Type 1 and 3 collagens in
atheromatous plaque [27] might also explain the pre-
dominance of collagen fragments, especially since plaque
burden increases with age [28]. In older subjects the col-
lagen concentration in atheromatous plaque increases in
areas close to the arterial lumen [29] and is therefore in
closer contact with the blood stream.
Synthesis or degradation of collagens is slow in a
healthy arterial system [30], which may imply decreased
levels of collagen fragments in the blood stream of
healthy individuals. In atheromatous plaque the main
component of the fibrous cap, the region in contact with
the circulating blood, consists of types 1 and 3 collagens
[31]. Atherosclerosis causes an increased synthesis and
degradation of many matrix components [32], and the
CAD238 score derived from urinary proteomics may rep-
resent a measure of collagen turnover and thereby repre-
sent a biomarker of cardiovascular disease.
Significant CAD not only affects the coronary vessel
walls but also the myocardium by transient or perman-
ent ischemia; for example in myocardium with exercise
induced perfusion deficits or hibernating myocardium.
Considering the statistically significant differences in
CAD238 score after correction of the Gensini score as
well as the high CAD238 score in prognostically relevant
CAD, myocardial ischemia on its own or in addition to
cardiac atherosclerosis could potentially contribute to
the urinary proteome in patients with CAD. Transient
[33] or permanent [34] inadequate myocardial perfusion
leads to localized inflammation and increased interstitial
fibrosis. As myocardial fibrosis is characterized by accu-
mulation of collagen types 1 and 3 within the intercellular
space [35], this quantity change implies increased collagen
degradation and hence a rise in collagen fragments.
Study limitations
The main finding of the present study, i.e. the relationship
between CAD238 score and CAD extent, is at the same
time the major limitation of urine proteomics as a diag-
nostic tool for CAD. Indeed, our present findings suggest
that the CAD-specific urinary polypeptide pattern is re-
lated to CAD extent and it should of course be noted that
normal coronary angiography results do not exclude early
forms of coronary atherosclerosis. The polypeptide pattern
could in addition to or instead of coronary atherosclerosis
identify flow limiting CAD with consecutive myocardial fi-
brosis. Therefore, additional investigations are required to
determine the origin of the CAD238 score.
A further limitation of the present study is its retro-
spective design. Urine samples were collected after cor-
onary angiography, which included PCI in 77 % of the
cases. It is therefore possible that the CAD238 score
could differentiate between patients with stable angina
with and without CAD in a prospective study if the sam-
ples had been taken prior to PCI.
Conclusions
We have previously shown that polypeptide patterns de-
rived form urine proteomics provides good diagnostic
accuracy for severe CAD. The CAD238 score is, however,
of limited diagnostic value in patients with stable
angina-like chest pain who have less extensive CAD.
Furthermore, the CAD238 score reflects on CAD extent
suggesting that the score has potential for prognostica-
tion but is less useful for diagnosis in patients with
stable angina if not complemented by other diagnostic
tests. However, our data support the association of urin-
ary peptides with CAD and provide a rationale for fur-
ther development of diagnostic proteomic biomarkers.
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